DarioHealth has bought fellow digital health specialist Twill for $10 million upfront, plus another 10 million in stock worth upwards of $20 million, in a move that combin
In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica
RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma
The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therap
Views & Analysis
White Papers & Webinar
Podcasts & Video
The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs.
A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place
According to the FDA, 2024 will be the ’breakout year’ for gene therapies.
In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.